Article Figures & Data
Figures
- 1
CAL-101 and bortezomib synergistically interact in Z138, HBL-2, and Jeko-1 cells. (A) CAL-101/bortezomib combination significantly suppressed viability of MCL cells compared with single-agent CAL-101 or BTZ through MTT. (B) CAL-101/bortezomib combination induced significantly synergistic cytotoxicity in MCL cells by CalcuSyn software calculation [Combination index (CI) <1.0]. CI values <1.0 indicates a synergistic interaction and CI values >1.0 indicates antagonistic drug effects. A straight line at CI =1.0 represents additive effects of both drugs. (C) Inhibitory effect of CAL-101 on the viability of Z138, HBL-2, and Jeko-1 cells was time dependent.
- 2
Combined treatment with CAL-101 and bortezomib synergistically induces apoptosis in MCL cells. (A) Annexin-V/PI assay indicated that CAL-101/BTZ combination obviously induced cell apoptosis in two cell lines. (B) Bar chart showed that the combined treatment produced enhanced apoptosis in both cell lines.
- 3
CAL-101 inhibits the PI3K/AKT and ERK pathway. (A) PI3K-p110σ was expressed in MCL cell lines. (B) The expression of P-AKT and P-ERK decreased with increasing concentration of CAL-101.
- 4
(A) NF-κB Inactivation is enhanced by CAL-101/Bortezomib combination. (B) Combined treatment induced marked downregulation of p-AKT in MCL cells. (C) Caspase-3 was up-regulated after combined treatment in MCL cell lines.
In this issue
Jump to section
Related Articles
Cited By...
- No citing articles found.